Eupraxia Pharmaceuticals ... (EPRX)
3.08
0.03 (0.98%)
At close: Jan 15, 2025, 3:58 PM
3.08
0.00%
After-hours Jan 15, 2025, 03:59 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |
| Gross Profit | -209.91K | -193.27K | -111.53K | -116.81K | -201.94K | -125.83K | -85.38K |
| Operating Income | -36.90M | -22.63M | -20.87M | -2.25M | -6.15M | -14.31M | -4.97M |
| Interest Income | 407.04K | 569.32K | 65.73K | 427.00 | 12.04K | 1.11K | 330.00 |
| Pretax Income | -39.18M | -23.92M | -23.37M | -4.01M | -7.24M | -14.83M | -5.00M |
| Net Income | -37.39M | -23.26M | -22.99M | -4.00M | -7.18M | -13.23M | -4.32M |
| Selling & General & Admin | 9.65M | 5.81M | 8.89M | 1.27M | 3.01M | 7.54M | 1.70M |
| Research & Development | 27.54M | 17.20M | 9.68M | 859.78K | 2.94M | 6.64M | 3.19M |
| Other Expenses | n/a | n/a | -2.26M | n/a | 1.74K | n/a | n/a |
| Operating Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Interest Expense | 1.58M | 1.59M | 1.30M | 1.88M | 1.46M | 142.17K | 52.81K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 37.92M | 23.20M | 18.68M | 2.25M | 6.16M | 14.31M | 4.97M |
| Income Tax | -89.67K | 930.52K | -1.34M | 1.87M | 1.40M | -1.46M | -627.56K |
| Shares Outstanding (Basic) | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
| Shares Outstanding (Diluted) | 24.15M | 19.29M | 14.24M | 12.87M | 12.87M | 12.87M | 12.87M |
| EPS (Basic) | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| EPS (Diluted) | -1.58 | -1.21 | -1.61 | -0.31 | -0.56 | -1.03 | -0.34 |
| EBITDA | -36.75M | -22.14M | -21.96M | -2.01M | -5.94M | -14.57M | -4.89M |
| Depreciation & Amortization | 209.91K | 193.27K | 111.53K | 116.81K | 201.94K | 125.83K | 85.38K |